Neuland Laboratories (524558) Q4 14/15 earnings summary

Executive summary

• FY15 was a transition year: topline was nearly flat, while EBITDA and PAT declined amid Q3 facility renovation, higher employee costs and manufacturing expenses.

• Strategy remained focused on pure-play APIs, shifting toward complex, high-margin molecules while expanding Custom Manufacturing Solutions (CMS) and mainstream volume products.

• Business reorganization was largely completed, including a stronger balance sheet after the rights issue, expanded R&D capabilities, a broader customer base and the Mitsubishi Chemicals collaboration.

Financial highlights

• Standalone total income was ₹46,993.22 lacs vs ₹46,910.81 lacs in FY14; net revenue from operations was ₹46,470.35 lacs vs ₹46,569.33 lacs.

• EBITDA was ₹6,714.55 lacs, down from ₹7,371.38 lacs; EBITDA margin was 14.3% vs 15.7% in FY14.

• PAT was ₹1,578.13 lacs vs ₹2,666.75 lacs; basic EPS was ₹18.47 vs ₹32.16, adjusted for the rights issue bonus element.

• Operating cash flow was ₹1,306.53 lacs vs ₹4,852.83 lacs; cash generated before tax and working-capital effects was ₹2,207.85 lacs vs ₹5,186.14 lacs.

Outlook and guidance

• FY16 growth drivers include high-value APIs, CMS and volume-accretive mainstream products; the new Mitsubishi Chemicals-linked facility was expected to reach near-optimal utilization in FY16.

• Long-term EBITDA margin aspiration was ~18-20%, supported by niche APIs, CMS growth, geographic expansion, process efficiencies and capacity debottlenecking.

• Plans included scaling up 12 products in FY16, developing 12 new products, adding 10-15 APIs annually and building a portfolio of 125+ products with 150+ patent filings over the medium to long term.

• CMS contracts and projects were progressing, with management expecting some projects to significantly drive growth; no similar renovation or audit-related disruption was anticipated in the near term.